Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma

被引：0
|
作者：
Liu, Zhuowei
Jiang, Lijuan
Li, Xiangdong
Ye, Yunlin
Wu, Zhiming
An, Xin
Shi, Yanxia
Yao, Kai
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Urol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16563
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+locally advanced or metastatic urothelial carcinoma (UC) in Asian patients
    Ye, D.
    Liu, J.
    Zhou, A.
    Zou, Q.
    Li, H.
    Fu, C.
    Hu, H.
    Huang, J.
    Zhu, S.
    Jin, J.
    Ma, L.
    Guo, J.
    Xiao, J.
    Park, S. H.
    Zhang, D.
    Qiu, X.
    Bao, Y.
    Zhang, L.
    Shen, W.
    Feng, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 367 - 367
  • [2] RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.
    Zhou, Li
    Xu, Huayan
    Yan, Xieqiao
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Li, Siming
    Bai, Xue
    Guo, Jun
    Sheng, Xinan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial
    Apolo, A. B.
    Infante, J. R.
    Hamid, O.
    Patel, M.
    Wang, D.
    Kelly, K.
    Mega, A.
    Britten, C. D.
    Mita, A.
    Ravaud, A.
    Cuillerot, J. M.
    Von Heydebreck, A.
    Gulley, J. L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S522 - S522
  • [4] Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS']JS001, an anti-PD-1 monoclonal antibody.
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Tang, Bixia
    Yan, Xieqiao
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
    Msaouel, Pavlos
    Sweis, Randy F.
    Bupathi, Manojkumar
    Heath, Elisabeth
    Goodman Jr, Oscar B.
    Hoimes, Christopher J.
    Milowsky, Matthew I.
    Davis, Nancy
    Kalebasty, Arash Rezazadeh
    Picus, Joel
    Shaffer, David
    Mao, Shifeng
    Adra, Nabil
    Yorio, Jeffrey
    Gandhi, Sunil
    Grivas, Petros
    Siefker-Radtke, Arlene
    Yang, Rui
    Latven, Lisa
    Olson, Peter
    Chin, Curtis D.
    Der-Torossian, Hirak
    Mortazavi, Amir
    Iyer, Gopa
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 933 - 943
  • [6] Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study
    Sandhu, S.
    Hill, A.
    Gan, H.
    Friedlander, M.
    Voskoboynik, M.
    Barlow, P.
    Townsend, A.
    Song, J.
    Zhang, Y.
    Liang, L.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 28 - 28
  • [7] Combination therapy with PD-1 antibody and hedgehog inhibitor for locally advanced basal cell carcinoma and metastatic melanoma
    Prien, L. M.
    Weishaupt, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 110 - 110
  • [8] ARIES: A PHASE 2, OPEN-LABEL STUDY TO EVALUATE RUCAPARIB (PARP INHIBITOR) IN COMBINATION WITH NIVOLUMAB (ANTI-PD-1 ANTIBODY) IN PATIENTS WITH OVARIAN OR UROTHELIAL CANCER (UC)
    Moore, K.
    Redhead, K.
    Goble, S.
    Bowles, O.
    Lin, K. K.
    Tripathi, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A130 - A130
  • [9] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [10] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
12345